We previously demonstrated that a ratio of BCL2 expression with the resistance factors MCL1 and BCL2L1 could predict sensibility to venetoclax in MCL and MM ex vivo and in vivo (20, 39, 40). This evidence concerns the gene MCL1 and Miyoshi myopathy.